ODTXOdyssey Therapeutics, Inc.
$18.09
$18.09
$15.5652 weeks$28.84
ODTX in its own filings
Nothing in ODTX's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
7
Events found in the filings · across 68 filings · the record starts in 2026
- Hard flags
- none
Hard flags
- Most recent filing
- Sep 9, 2026
Most recent filing · Form 8-K
- Record starts
- May 11, 2026
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filinga quarter after the last one
- expected around Nov 3, 2026
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 9, 2026Corporate Presentation September 2026.Regulation FD disclosure · press release
- Aug 4, 2026Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
- Jun 23, 2026Corporate Presentation June 2026.Regulation FD disclosure · press release
- Jun 17, 2026Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
- May 11, 2026On May 7, 2026, Odyssey Therapeutics, Inc. (the “Company”) entered into a Share Purchase Agreement (the “Purchase Agreement”) with TPG LSI Rise Orazio II, L.P. (“Purchaser”), an affiliate of an existing stockholder of the Company, for the purchase of an aggregate of 1,388,889 shares (the “Shares”) of the Company’s …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Biotechnology
The closest names by size in the same industry